China based conglomerate AUX Group has announced plans to seek health services investments in the US and Britain, according to recent reports. The company has 8.2 billion USD in total assets and was named among China’s top 500 enterprises. The announcement comes after AUX Group’s planned 2.7 billion AUD investment into Healthscope, the second-largest operator of private hospitals in Australia, sank due to delayed Foreign Investment Review Board (FIRB) approval.
AUX Group had annual revenues of 13.5 billion USD in 2015 and owns three listed companies, as well as the largest private hospital in the Zhejiang province of China. Following the unexpected complications in the FIRB process, AUX is suspending its foray into Australia to focus on British and American healthcare opportunities.
According to figures provided by the IMS Institute, global medicine sales will grow by between 290 billion USD and 320 billion USD from 2013 to 2018, representing a huge increase on the growth between 2008 and 2013. In 2018, total global medicine sales will reach between 1.28 and 1.31 trillion USD.
New treatments are expected to be an important factor in this increased growth, which will also depend on the demands of healthcare markets with rapidly ageing populations and rising levels of treatable diseases.
In China, these will mainly take the form of lifestyle-oriented diseases – with levels of obesity increasing rapidly along with rising wealth and the expansion of the middle class, the incidence rate of diabetes, high cholesterol, hypertension and impaired mobility and other associated disorders are rising as well. The country’s healthcare industry will need injections of capital and innovation in order to keep up with these changes and the resulting demand for treatments.
Major Chinese investors are stepping in to provide these necessities, partly through investments into healthcare ventures and opportunities. Dalian Wanda Group, for example, has pledged 2.3 billion USD to hospital developments, marking its first entry into the healthcare sector.
Naseba is a multinational business facilitation company that specialises in providing business cases and project holders with exactly these connections and expertise. We have spent over a decade building an extensive network of investor contacts worldwide – including in China – and leveraging this network for deal facilitation purposes. Our investor analysts have carried out intensive research with Chinese investors, gathering survey results and data regarding their specific investment preferences.
Based on this research, our investor introduction division sources and pre-qualifies business cases on behalf of Chinese investors. They are then introduced through private meetings and investor roadshows.
On 7th , December 2016, we will be organising a private investor meeting in Shanghai, China to introduce pre-screened Chinese investors to pre-qualified US healthcare investment opportunities.
Submit your business case:
Oops! We could not locate your form.
To learn more, contact:
Naseba investor introduction
+971 4 455 7954